What are the treatment options for an adult with pulmonary hypertension not caused by primary lung disease?

Treatment of Pulmonary Hypertension Not Caused by Primary Lung Disease

For treatment-naïve adults with pulmonary arterial hypertension (PAH) WHO functional class II-III, initial combination therapy with ambrisentan plus tadalafil is recommended over monotherapy, as this approach has proven superior in delaying clinical failure. 1

Initial Treatment Strategy Based on Disease Severity

WHO Functional Class II-III Patients

Preferred approach: Initial combination therapy

• Ambrisentan + Tadalafil is the evidence-based first choice (weak recommendation, moderate quality evidence) 1
• If patients are unwilling or unable to tolerate combination therapy due to cost, multiple medications, or potential adverse events, monotherapy options include:
  • Bosentan, macitentan, or ambrisentan (endothelin receptor antagonists)
  • Sildenafil or tadalafil (PDE-5 inhibitors)
  • Riociguat (soluble guanylate cyclase stimulator) 1

WHO Functional Class III with Rapid Progression or Poor Prognosis

Initiate parenteral prostacyclin therapy immediately:

• IV epoprostenol (prioritized - has demonstrated mortality reduction in high-risk patients) 2
• IV treprostinil or subcutaneous treprostinil as alternatives 1

WHO Functional Class IV Patients

Continuous IV epoprostenol, IV treprostinil, or SC treprostinil is recommended 1

• Start epoprostenol at 2 ng/kg/min and increase as tolerated 1
• If parenteral therapy is not feasible: inhaled prostanoid combined with oral PDE-5 inhibitor and oral endothelin receptor antagonist 1

Sequential Therapy for Inadequate Response

When patients show inadequate clinical response to initial therapy:

1. On monotherapy → Add second drug class from a different mechanism 2, 1
2. On dual therapy → Add third drug class to achieve triple combination 2, 1
3. Note: Riociguat and PDE-5 inhibitors are contraindicated together 2

Available Drug Classes and Dosing

Endothelin Receptor Antagonists

• Bosentan: 125 mg twice daily
• Ambrisentan: 5-10 mg once daily
• Macitentan: 10 mg once daily 1

PDE-5 Inhibitors

• Sildenafil: 20 mg every 8 hours
• Tadalafil: 40 mg once daily 1

Prostacyclin Pathway Agents

• Epoprostenol: IV infusion starting 2 ng/kg/min
• Treprostinil: Multiple routes (IV, SC, inhaled, oral)
• Iloprost: Inhaled 2.5-5.0 mg, 6-9 inhalations daily 1

Soluble Guanylate Cyclase Stimulator

• Riociguat: 0.5-1.0 mg every 8 hours, titrate to maximum 2.5 mg 1

Prostacyclin Receptor Agonist

• Selexipag: Start 200 mg twice daily, increase to maximum 1,600 mg twice daily 1

Essential Supportive Care Measures

All PAH patients should receive: 1

• Evaluation at specialized pulmonary hypertension centers
• Systematic severity assessment using consistent risk stratification
• Aggressive treatment of contributing causes
• Supervised exercise activity programs
• Influenza and pneumococcal immunizations
• Pregnancy avoidance (when pregnancy occurs, manage at PH center)
• Supplemental oxygen to maintain saturations >91% at high altitude or during air travel
• Avoidance of non-essential surgery (when necessary, perform at PH center)
• Early incorporation of palliative care services

Advanced Therapies for Refractory Disease

For patients failing maximal pharmacotherapy: 2

• Lung transplantation is recommended after inadequate response to maximal medical therapy (Class I recommendation)
• Bilateral lung transplantation is the predominant approach worldwide 2
• Balloon atrial septostomy may be considered where available (Class IIb recommendation) 2
• Veno-arterial ECMO can bridge awake end-stage patients to transplantation 2

Critical Pitfalls to Avoid

1. Do not use pulmonary vasodilators in Group 2 (left heart disease) or Group 3 (lung disease) PH - these have not proven safe or effective 3
2. Never combine riociguat with PDE-5 inhibitors - this is contraindicated 2
3. Do not delay referral to specialized centers - early expert evaluation improves outcomes 1
4. Avoid calcium channel blockers without vasoreactivity testing - only a small subset of patients respond 2

Special Consideration: Chronic Thromboembolic PH (Group 4)

For patients with chronic thromboembolic pulmonary hypertension:

• Pulmonary endarterectomy is the treatment of choice 3, 4
• For inoperable patients: riociguat has proven efficacy 3, 4
• Balloon pulmonary angioplasty is an emerging interventional option 4

The treatment paradigm has shifted toward early aggressive combination therapy based on risk stratification, with the goal of achieving low-risk status rather than targeting single parameters. This approach has dramatically improved survival rates from 30-40% to over 85% at three years. 4